Lung cancer diagnostic and screening Market remains a significant health concern worldwide, with smoking being a major risk factor. However, lung cancer can also occur in non-smokers, emphasizing the importance of comprehensive diagnosis and screening strategies. In this blog, we will explore valuable insights into lung cancer diagnosis and screening, looking beyond the traditional association with smoking and highlighting the broader scope of this disease.
Liquid biopsy is an emerging non-invasive diagnostic tool in lung cancer. This approach involves analysing circulating tumour DNA (ctDNA) or other biomarkers present in a patient’s blood sample. Liquid biopsy offers a less invasive alternative to traditional tissue biopsy and can provide real-time information about tumour characteristics, genetic mutations, and treatment response.
Screening programs, particularly for high-risk individuals such as long-term smokers, are instrumental in identifying Lung Cancer Diagnostic And Screening Market in its early stages. Low-dose CT screening has demonstrated promising results in detecting lung cancer at an early, treatable stage, leading to reduced mortality rates. These screening programs enable healthcare professionals to detect lung cancer before symptoms manifest, allowing for timely interventions and personalized treatment plans.